The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis
Abstract
Two prior double‐blind, placebo‐controlled, randomized trials demonstrated that glatiramer acetate (GA) reduces relapse rates in patients with relapsing remitting multiple sclerosis (RRMS). This study was designed to determine the effect, onset, and durability of any effect of GA on disease activity monitored with magnetic resonance imaging (MRI) in patients with RRMS. Two hundred thirty‐nine eligible patients were randomized to receive either 20 mg GA (n = 119) or placebo (n = 120) by daily subcutaneous injection. Eligibility required one or more relapses in the 2 years before entry and at least one enhancing lesion on a screening MRI. The study was a randomized, double‐blind, placebo‐controlled phase during which all patients studied underwent monthly MRI scans and clinical assessments over 9 months. The primary outcome measure was the total number of enhancing lesions on T1‐weighted images. Secondary outcome measures included the proportion of patients with enhancing lesions, the number of new enhancing lesions and change in their volume; the number of new lesions detected on T2‐weighted images and change in their volume, and the change in volume of hypointense lesions seen on unenhanced T1‐weighted images. Clinical measures of disease activity were also evaluated. The active treatment and placebo groups were comparable at entry for all demographic, clinical, and MRI variables. Treatment with GA showed a significant reduction in the total number of enhancing lesions compared with placebo (−10.8, 95% confidence interval −18.0 to −3.7; p = 0.003). Consistent differences favoring treatment with GA were seen for almost all secondary end points examined: number of new enhancing lesions (p < 0.003), monthly change in the volume of enhancing lesions (p = 0.01), and change in volume (p = 0.006) and number of new lesions seen on T2‐weighted images (p < 0.003). The relapse rate was also significantly reduced by 33% for GA‐treated patients (p = 0.012). All effects increased over time. Glatiramer acetate significantly reduced MRI‐measured disease activity and burden. Ann Neurol 2001;49:290–297
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis
Jacobs, L. D., Cookfair, D. L., Rudick, R. A., Herndon, R. M., Richert, J. R., Salazar, A. M., Fischer, J. S., Goodkin, D. E., Granger, C. V., Simon, J. H., et al. (1996) · Annals of Neurology · doi:10.1002/ana.410390304 · Cited by 2,450
Ebers, G. C. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03334-0 · Cited by 2,073
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1995) · Neurology · doi:10.1212/wnl.45.7.1268 · Cited by 1,898
Self-citationHauser, S. L., Dawson, D. M., Lehrich, J. R., Beal, M. F., Kevy, S. V., Propper, R. D., Mills, J. A., & Weiner, H. L. (1983) · New England Journal of Medicine · doi:10.1056/nejm198301273080401 · Cited by 827
Johnson, K. P., Brooks, B. R., Cohen, J. A., Ford, C. C., Goldstein, J., Lisak, R. P., Myers, L. W., Panitch, H. S., Rose, J. W., Schiffer, R. B., et al. (1998) · Neurology · doi:10.1212/wnl.50.3.701 · Cited by 509
Self-citationKappos, L., Moeri, D., Radue, E. W., Schoetzau, A., Schweikert, K., Barkhof, F., Miller, D., Guttmann, C. R., Weiner, H. L., Gasperini, C., et al. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03053-0 · Cited by 499 · cited 7×
“This study was designed to evaluate the effect of GA on MRI-monitored features of the pathology of MS.”
ResultSelf-citationA Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple Sclerosis
Bornstein, M. B., Miller, A., Slagle, S., Weitzman, M., Crystal, H., Drexler, E., Keilson, M., Merriam, A., Wassertheil-Smoller, S., Spada, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198708133170703 · Cited by 462
Miller, D. H., Albert, P. S., Barkhof, F., Francis, G., Frank, J. A., Hodgkinson, S., Lublin, F. D., Paty, D. W., Reingold, S. C., & Simon, J. (1996) · Annals of Neurology · doi:10.1002/ana.410390104 · Cited by 444
Cited by
Multiple Sclerosis: An Immune or Neurodegenerative Disorder?
Trapp, B. D., & Nave, K.-A. (2008) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094313 · Cited by 1,724
Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis
Brinkmann, V., Billich, A., Baumruker, T., Heining, P., Schmouder, R., Francis, G., Aradhye, S., & Burtin, P. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3248 · Cited by 1,273
A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Miller, D. H., Khan, O. A., Sheremata, W. A., Blumhardt, L. D., Rice, G. P. A., Libonati, M. A., Willmer-Hulme, A. J., Dalton, C. M., Miszkiel, K. A., & O'Connor, P. W. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020696 · Cited by 1,242
The clinico-radiological paradox in multiple sclerosis revisited
Barkhof, F. (2002) · Current Opinion in Neurology · doi:10.1097/00019052-200206000-00003 · Cited by 726
Wattjes, M. P., Ciccarelli, O., Reich, D. S., Banwell, B., de Stefano, N., Enzinger, C., Fazekas, F., Filippi, M., Frederiksen, J., Gasperini, C., et al. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00095-8 · Cited by 674
Self-citationComi, G., Martinelli, V, Rodegher, M., Moiola, L., Bajenaru, O., Carra, A., Elovaara, I., Fazekas, F., Hartung, H., Hillert, J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61259-9 · Cited by 592
Self-citationMikol, D. D., Barkhof, F., Chang, P., Coyle, P. K., Jeffery, D. R., Schwid, S. R., Stubinski, B., & Uitdehaag, B. M. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70200-x · Cited by 486
on behalf of the MAGNIMS study group (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2015.157 · Cited by 473
Treatment of multiple sclerosis with the pregnancy hormone estriol
Sicotte, N. L., Liva, S. M., Klutch, R., Pfeiffer, P., Bouvier, S., Odesa, S., Wu, T. C. J., & Voskuhl, R. R. (2002) · Annals of Neurology · doi:10.1002/ana.10301 · Cited by 435
Wolinsky, J. S., Narayana, P. A., O'Connor, P., Coyle, P. K., Ford, C., Johnson, K., Miller, A., Pardo, L., Kadosh, S., Ladkani, D., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21079 · Cited by 429
Self-citationO'Connor, P., Filippi, M., Arnason, B., Comi, G., Cook, S., Goodin, D., Hartung, H.-P., Jeffery, D., Kappos, L., Boateng, F., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70226-1 · Cited by 405
Self-citationA Phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses
O’Connor, P. W., Li, D., Freedman, M. S., Bar-Or, A., Rice, G. P. A., Confavreux, C., Paty, D. W., Stewart, J. A., & Scheyer, R. (2006) · Neurology · doi:10.1212/01.wnl.0000203121.04509.31 · Cited by 358
García-Lorenzo, D., Francis, S., Narayanan, S., Arnold, D. L., & Collins, D. L. (2013) · Medical Image Analysis · doi:10.1016/j.media.2012.09.004 · Cited by 355
Treatment of multiple sclerosis — success from bench to bedside
Tintore, M., Vidal-Jordana, A., & Sastre-Garriga, J. (2019) · Nature Reviews Neurology · doi:10.1038/s41582-018-0082-z · Cited by 343
Is it time to target no evident disease activity (NEDA) in multiple sclerosis?
Giovannoni, G., Turner, B., Gnanapavan, S., Offiah, C., Schmierer, K., & Marta, M. (2015) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2015.04.006 · Cited by 338
Vitamin D status is associated with relapse rate in pediatric‐onset multiple sclerosis
Mowry, E. M., Krupp, L. B., Milazzo, M., Chabas, D., Strober, J. B., Belman, A. L., McDonald, J. C., Oksenberg, J. R., Bacchetti, P., & Waubant, E. (2010) · Annals of Neurology · doi:10.1002/ana.21972 · Cited by 329
Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
De Stefano, N., Giorgio, A., Battaglini, M., Rovaris, M., Sormani, M. P., Barkhof, F., Korteweg, T., Enzinger, C., Fazekas, F., Calabrese, M., et al. (2010) · Neurology · doi:10.1212/wnl.0b013e3181e24136 · Cited by 321
Self-citationKeegan, B. M., & Noseworthy, J. H. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103909 · Cited by 319
Evolving concepts in the treatment of relapsing multiple sclerosis
Comi, G., Radaelli, M., & Soelberg Sørensen, P. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32388-1 · Cited by 306
Self-citationDisease‐modifying treatments for multiple sclerosis – a review of approved medications
Torkildsen, Ø., Myhr, K. ‐., & Bø, L. (2016) · European Journal of Neurology · doi:10.1111/ene.12883 · Cited by 280
MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
Sormani, M. P., & Bruzzi, P. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70103-0 · Cited by 278
Comi, G., Pulizzi, A., Rovaris, M., Abramsky, O., Arbizu, T., Boiko, A., Gold, R., Havrdova, E., Komoly, S., Selmaj, K., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60918-6 · Cited by 278
Self-citationHong, J., Li, N., Zhang, X., Zheng, B., & Zhang, J. Z. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0502187102 · Cited by 264
Song, Y., Li, J., & Wu, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01952-8 · Cited by 259
Treatment strategies for multiple sclerosis: When to start, when to change, when to stop?
Gajofatto, A., & Benedetti, M. D. (2015) · World Journal of Clinical Cases · doi:10.12998/wjcc.v3.i7.545 · Cited by 256
Glatiramer acetate: mechanisms of action in multiple sclerosis.
Ziemssen, T., & Schrempf, W. (2007) · International review of neurobiology · doi:10.1016/s0074-7742(07)79024-4 · Cited by 135
Tilling, K., Lawton, M., Robertson, N., Tremlett, H., Zhu, F., Harding, K., Oger, J., & Ben-Shlomo, Y. (2016) · Health Technology Assessment · doi:10.3310/hta20810 · Cited by 43
Metadata
- Authors
- Comi, G., Filippi, M., Wolinsky, J. S., & European/Canadian Glatiramer Acetate Study Group
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2001-03
- Volume
- 49
- Issue
- 3
- Pages
- 290-297
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W4366064463
- Cited by
- 650
- References
- 32
- FWCI
- 23.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.